Do you have a need to understand the fast moving prostate cancer market and its competitive dynamics? If so, please contact us as we offer a number of services in support of prostate cancer marketing and new products. The team at Icarus Consultants has in-depth knowledge of this therapeutic area.
Last week, Pieter Droppert wrote on Biotech Strategy Blog about what the impact of the European approval for abiraterone acetate (Zytiga®) may be on cabazitaxel (Jevtana®) sales.
Both are indicated in the post-docetaxel setting. Will physicians prescribe a convenient pill (abiraterone) as opposed to using another line of chemo (cabazitaxel)? You can read Pieter’s thoughts on Biotech Strategy Blog.
Meanwhile on Pharma Strategy Blog, Sally Church wrote an update on pharma social media. She reviewed the Zytiga healthcare professionals website and the many features that she liked.
In another post last week, Sally discussed some of the issues surrounding the drop in share price for Dendreon and possible reasons for poor sipuleucel-T (Provenge®) sales. She also discussed new research that shows the TMPRSS2:ERG gene may be a more useful marker than PSA in prostate cancer. You can read more on Pharma Strategy Blog.
Want to understand the prostate cancer market? Contact us.